3.38  0 (0%)		09-18 16:00
Open: 3.36 High: 3.54 Volume: 196,486		Pre. Close: 3.38 Low: 3.27 Market Cap: 104(M)

Short term
Mid term
Targets	6-month :	4.6	1-year :	5.37
Resists	First :	3.94	Second :	4.6
Pivot price	3.2
Supports	First :	2.98	Second :	2.39
MAs	MA(5) :	3.47	MA(20) :	3.15
	MA(100) :	3.73	MA(250) :	5.05
MACD	MACD :	0.1	Signal :	0
%K %D	K(14,3) :	63.3	D(3) :	68.8
RSI	RSI(14): 53.7
52-week	High :	20.7	Low :	2.13

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SGMT ] has closed below upper band by 38.3%. Bollinger Bands are 23.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.55 - 3.56	3.56 - 3.58
Low:	3.22 - 3.24	3.24 - 3.27
Close:	3.34 - 3.38	3.38 - 3.41

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Thu, 12 Sep 2024
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit - GlobeNewswire

Thu, 12 Sep 2024
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit - StockTitan

Wed, 04 Sep 2024
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences - GlobeNewswire

Wed, 04 Sep 2024
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences - StockTitan

Mon, 12 Aug 2024
Sagimet Biosciences Inc. (SGMT): Should You Buy This New Penny Stock Now? - Insider Monkey

Wed, 31 Jul 2024
Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	31 (M)
Held by Insiders	1.62e+007 (%)
Held by Institutions	14.1 (%)
Shares Short	1,690 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	813.7 %
Return on Equity (ttm)	-21.6 %
Qtrly Rev. Growth	2e+006 %
Gross Profit (p.s.)	0
Sales Per Share	0.06
EBITDA (p.s.)	0
Qtrly Earnings Growth	-1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-23 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	51.34
Price to Cash Flow	0

Dividend	0
Forward Dividend	1.86e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.